Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Targeted ED-B fibronectin SPECT in vivo imaging in experimental atherosclerosis.

Dietrich T, Berndorff D, Heinrich T, Hucko T, Stepina E, Hauff P, Dinkelborg LM, Atrott K, Giovannoni L, Neri D, Fleck E, Graf K, Menssen HD.

Q J Nucl Med Mol Imaging. 2015 Jun;59(2):228-37.

PMID:
25864530
2.

18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.

Chang E, Liu H, Unterschemmann K, Ellinghaus P, Liu S, Gekeler V, Cheng Z, Berndorff D, Gambhir SS.

Clin Cancer Res. 2015 Jan 15;21(2):335-46. doi: 10.1158/1078-0432.CCR-14-0217. Epub 2014 Nov 7.

3.

Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of human tumor xenografts.

Chang E, Liu S, Gowrishankar G, Yaghoubi S, Wedgeworth JP, Chin F, Berndorff D, Gekeler V, Gambhir SS, Cheng Z.

Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):722-30. doi: 10.1007/s00259-010-1672-1. Epub 2010 Dec 2.

PMID:
21125268
4.

D-18F-fluoromethyl tyrosine imaging of bone metastases in a mouse model.

Zitzmann-Kolbe S, Strube A, Frisk AL, Käkönen SM, Tsukada H, Hauff P, Berndorff D, Graham K.

J Nucl Med. 2010 Oct;51(10):1632-6. doi: 10.2967/jnumed.110.078899. Epub 2010 Sep 16.

5.

Direct one-step 18F-labeling of peptides via nucleophilic aromatic substitution.

Becaud J, Mu L, Karramkam M, Schubiger PA, Ametamey SM, Graham K, Stellfeld T, Lehmann L, Borkowski S, Berndorff D, Dinkelborg L, Srinivasan A, Smits R, Koksch B.

Bioconjug Chem. 2009 Dec;20(12):2254-61. doi: 10.1021/bc900240z.

PMID:
19921791
6.

Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V.

J Nucl Med. 2009 May;50(5):781-9. doi: 10.2967/jnumed.108.056929. Epub 2009 Apr 16.

7.

Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks.

Höhne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, Stellfeld T, Borkowski S, Berndorff D, Klar U, Voigtmann U, Cyr JE, Friebe M, Dinkelborg L, Srinivasan A.

Bioconjug Chem. 2008 Sep;19(9):1871-9. doi: 10.1021/bc800157h. Epub 2008 Aug 28.

PMID:
18754574
8.

MO tripeptide diastereomers (M=99/99mTc, Re): models to identify the structure of 99mTc peptide targeted radiopharmaceuticals.

Cantorias MV, Howell RC, Todaro L, Cyr JE, Berndorff D, Rogers RD, Francesconi LC.

Inorg Chem. 2007 Sep 3;46(18):7326-40. Epub 2007 Aug 11.

9.

Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin.

Rossin R, Berndorff D, Friebe M, Dinkelborg LM, Welch MJ.

J Nucl Med. 2007 Jul;48(7):1172-9. Epub 2007 Jun 15.

10.

Identification and evaluation of a new tumor cell-binding peptide, FROP-1.

Zitzmann S, Krämer S, Mier W, Hebling U, Altmann A, Rother A, Berndorff D, Eisenhut M, Haberkorn U.

J Nucl Med. 2007 Jun;48(6):965-72. Epub 2007 May 15.

11.

Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.

Berndorff D, Borkowski S, Moosmayer D, Viti F, Müller-Tiemann B, Sieger S, Friebe M, Hilger CS, Zardi L, Neri D, Dinkelborg LM.

J Nucl Med. 2006 Oct;47(10):1707-16.

12.

Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.

Moosmayer D, Berndorff D, Chang CH, Sharkey RM, Rother A, Borkowski S, Rossi EA, McBride WJ, Cardillo TM, Goldenberg DM, Dinkelborg LM.

Clin Cancer Res. 2006 Sep 15;12(18):5587-95.

13.

Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.

Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS, Cyr JE, Dinkelborg LM.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7053s-7063s.

14.

A high-affinity human antibody that targets tumoral blood vessels.

Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L.

Blood. 1999 Jul 1;94(1):192-8.

15.

LI-cadherin-mediated cell-cell adhesion does not require cytoplasmic interactions.

Kreft B, Berndorff D, Böttinger A, Finnemann S, Wedlich D, Hortsch M, Tauber R, Gessner R.

J Cell Biol. 1997 Mar 10;136(5):1109-21.

16.

Liver-intestine cadherin: molecular cloning and characterization of a novel Ca(2+)-dependent cell adhesion molecule expressed in liver and intestine.

Berndorff D, Gessner R, Kreft B, Schnoy N, Lajous-Petter AM, Loch N, Reutter W, Hortsch M, Tauber R.

J Cell Biol. 1994 Jun;125(6):1353-69.

Supplemental Content

Loading ...
Support Center